Clinical Trials Browser

lintuzumab × Myeloid × Clear all

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00283114 2014-12-18

A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Phase 1 Completed

82 enrolled

MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT00002800 2013-07-03

Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

Phase 2 Completed

60 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Blast Crisis, Leukemia, Myelodysplastic Syndromes, Neutropenia, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myelomonocytic, Chronic

NCT00002890 2013-06-25

Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia

Phase 1 Completed

24 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Blast Crisis, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT00502112 2011-10-12

A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)

Phase 1 Completed

13 enrolled

MyeloidOther hematologic neoplasm

Hematologic Diseases, Myelodysplastic Syndromes, Preleukemia

Clinical Trials

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia

A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)